ESMO Targeted Anticancer Therapies Asia Congress 2025: Abstracts
The abstract submission is now open!
Related Articles
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.
Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM
Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
BMT CTN Track to address new grant cycle, coordinators’ mental health, and real-world experiences – Tandem Meetings News
Blood and Marrow Transplant Clinical Trials Network Clinical Program Manager Mykala Heuer, BSN, RN, outlines highlights in the agenda, including discussions on operations, empowering coordinators,…
The Value of Clinical Pharmacists in Community Oncology
Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into community oncology practices.
Twin-Agent Therapy Evaluated for Philadelphia Chromosome-Positive ALL, CML in Lymphoid Blast Phase | Blood Cancers Today
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Development of LAVA-1207 Discontinues in mCRPC
The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.
Ohio State to partner with Zangmeister Cancer Center to expand access to cancer care
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Physicians and biopharma should improve accessibility of cancer trials – The Cancer Letter
Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!